Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present… Read More
Oxford, UK – 3 November 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, today publishes its interim management statement for the period from 1 July to 31 October 2014. Read More
Oxford, UK – 13 October 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, announces that it has acquired the freehold of the Windrush Court office and laboratory facilities in… Read More
Oxford, UK – 10 October 2014: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”) a leading gene and cell therapy company, announces today that it has signed further contracts with Novartis which build on the collaboration with… Read More
Oxford, UK – 28 August 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a world-leading gene and cell therapy company, today announces its unaudited interim results for the six months ended 30 June 2014. Read More
— Dr Paul Blake to take Executive Role as Chief Development Officer — Oxford, UK – 15 August 2014: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica”… Read More
Oxford, UK – 23 June 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today announces that it will attend Piper Jaffray’s GenomeRx Symposium on Monday, June 23, 2014 at The Yale… Read More
Oxford, UK – 18 June 2014: Oxford BioMedica (“the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announces that the Company has repaid in full the amount drawn down from the £5 million secured loan facility agreement, agreed on… Read More
Oxford, UK – 03 June 2014: Oxford BioMedica (“the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announced today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London. Read More
Oxford, UK – 13 May 2014: Oxford BioMedica plc (LSE:OXB), (“the Company”) the leading gene based biopharmaceutical company, today publishes its interim management statement for the period 1 January to 12 May 2014. OPERATIONAL HIGHLIGHTSLentiVector® platform product development Ocular portfolio… Read More
£2.2M award will be used to fund a Phase I/II clinical trial of Oxford Biomedica-102, an enhanced version of ProSavin®; a gene therapy for the treatment of Parkinson’s disease … Read More
Oxford, UK – 29 April 2014: Oxford BioMedica plc (LSE:OXB), (“the Company”) the leading gene based biopharmaceutical company, announces that it will regain the worldwide rights to RetinoStat… Read More